Eledon Pharmaceuticals, Inc. (ELDN) Q1 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

inhibitors help preserve graft survival, but they are also associated with significant side effects, such as hypertension, dyslipidemia, new onset of diabetes, and tremors. Moreover, research shows that 10-year post-transplant, almost all transplanted kidneys will demonstrate evidence of CNI-induced nephrotoxicity. We believe, based on the evidence generated to date, that tegoprubar has the potential to reduce or even potentially eliminate these side effects, while also providing improved graft function. Turning to the safety results we observed in the study, where among the three participants, Tegoprobar showed good tolerability, especially among a difficult to treat population. None of the participants experienced acute rejection, and there was no evidence of new onset diabetes after transplant or any impact on glucose level levels in two participants without diabetes at baseline. One participant was discontinued from the study on day 55 after developing BK viremia, a common occurrence following a kidney transplant, which occurs in 20% or more of transplant recipients. An additional participant elected to discontinue from the study after 33 weeks, reporting mild alopecia and mild insomnia, which the investigator did not attribute to Tago-Prubart. The adverse events continued once the patient was switched from Tago-Prubart to CNIs. We continue to make progress with this ongoing trial and have since enrolled an additional two participants who both remain on study. We expect to report updated data at a medical conference later this year. Building off our results from the ongoing Phase 1b trial, We remain on track to initiate our randomized open-label Phase II BESTO study to assess the safety and efficacy of tegoprobar compared to tacrolimus and the preservation of all...